In February 2020, OncoDNA raised EUR 19 million in a Series B financing round. Now the Belgian molecular profiling company has found a complementary acquisition target that will allow offering the whole value chain from genetic sequencing to clinical applications.

Written by

Investors

Verve Event Zurich Investors

Our sophisticated investors include visionary family offices, leading wealth managers, institutions, founders, and senior executives. These individuals and organizations are all committed to shaping the next generation of innovation.

Learn more

Privacy Preference Center